Balstilimab (NCT07551596)

Name: Balstilimab trial for Colorectal Adenocarcinoma (NCT07551596)
Uploaded: 2026-10-31T16:05:58.151Z
Duration: 1 min 15 s
Description: Balstilimab trial for Colorectal Adenocarcinoma (NCT07551596). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07551596.

Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial: a one-minute explainerNCT075515961 min

Balstilimab trial for Colorectal Adenocarcinoma (NCT07551596). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with stage II or III microsatellite-stable colorectal adenocarcinoma after standard treatment. Scans show no cancer, but a Signatera blood test detects residual tumor DNA.

The idea: give balstilimab infusions every three weeks for six months, with botensilimab in the first two six-week cycles. They block PD-1 and CTLA-4 immune brakes. Researchers test whether tumor DNA clears, while tracking recurrence and safety. Tumor biopsy is optional. Selected rectal-cancer patients under observation after complete response qualify.

This phase 2 study plans 20 patients. Kanwal Raghav leads two recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.